This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farrehi, P. M. Articles by Fay, W. P. Search for Related Content PubMed PubMed Citation Articles by Farrehi, P. M. Articles by Fay, W. P.

(Circulation. 1998;97:1002-1008.)
© 1998 American Heart Association, Inc.

Basic Science Reports

Regulation of Arterial Thrombolysis by Plasminogen Activator Inhibitor-1 in Mice

Peter M. Farrehi, MD; C. Keith Ozaki, MD; Peter Carmeliet, MD, PhD; ; William P. Fay, MD

From the Departments of Internal Medicine (P.M.F., W.P.F.) and Surgery (C.K.O.), University of Michigan Medical School, Ann Arbor; the Ann Arbor Veterans Affairs Hospital (W.P.F.); and the Center for Molecular and Vascular Biology (P.C.), University of Leuven (Belgium).

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Platelet-rich arterial thrombi are resistant to lysis by plasminogen activators. However, the mechanisms underlying thrombolysis resistance are poorly defined. Plasminogen activator inhibitor-1 (PAI-1), which is present in plasma, platelets, and vascular endothelium, may be an important determinant of the resistance of arterial thrombi to lysis. However, in vitro studies examining the regulation of platelet-rich clot lysis by PAI-1 have yielded inconsistent results.

Methods and Results—We developed a murine arterial injury model and applied it to wild-type (PAI-1 +/+) and PAI-1–deficient (PAI-1 -/-) animals. FeCl₃ was used to induce carotid artery thrombosis. Thrombi consisted predominantly of dense platelet aggregates, consistent with the histology of thrombi in large-animal arterial injury models and human acute coronary syndromes. To examine the role of PAI-1 in regulating endogenous clearance of platelet-rich arterial thrombi, thrombi were induced in 22 PAI-1 +/+ mice 14 PAI-1 -/- mice. Twenty-four hours later, the amount of residual thrombus was determined by histological analysis of multiple transverse sections of each artery. Residual thrombus was detected in 55 of 85 sections (64.7%) obtained from PAI-1 +/+ mice compared with 19 of 56 sections (33.9%) from PAI-1 -/- mice (P=.009). Computer-assisted planimetry analysis revealed that mean thrombus cross-sectional area was 0.033±0.027 mm² in PAI-1 +/+ mice versus 0.016±0.015 mm² in PAI-1 -/- mice (P=.048).

Conclusions—PAI-1 is an important determinant of thrombolysis at sites of arterial injury. Application of this model to other genetically altered mice should prove useful for studying the molecular determinants of arterial thrombosis and thrombolysis.

Key Words: thrombosis • thrombolysis • carotid arteries • plasminogen activators

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Vascular injury and subsequent thrombus formation are key events in the pathogenesis of several arterial diseases, including unstable angina pectoris, myocardial infarction, and stroke.¹ The blood fibrinolytic system, which functions to degrade intravascular fibrin, constitutes a critical response mechanism to arterial injury and thrombosis. Endogenously mediated fibrinolysis is initiated by t-PA and u-PA, enzymes that convert plasminogen to the fibrinolytic protease plasmin.² However, the rate and extent of thrombolysis after arterial injury can vary considerably in humans. In some individuals, arterial thrombi lyse spontaneously within several hours, whereas in others, thrombi fail to lyse, resulting in permanent vascular occlusion.³ This phenomenon is of considerable clinical importance in the setting of acute myocardial infarction, because early restoration of normal coronary artery blood flow is strongly associated with improved survival, and even delayed thrombolysis appears to exert beneficial effects on cardiac function.^{4 5} However, the molecular determinants of the lysis of arterial thrombi, which are characterized by a high platelet content, are not well understood. Although plasminogen activators trigger activation of the fibrinolytic pathway, multiple cofactors, inhibitors, and proteases contribute to the regulation of vascular fibrinolysis.^{2 6} Several studies suggest that PAI-1, which inhibits fibrinolysis by binding irreversibly to the active site of t-PA and u-PA, is a major determinant of the resistance of platelet-rich clots to lysis by t-PA.^{7 8 9 10 11} However, other studies suggest that PAI-1 plays only a minor role in regulating the lysis of platelet-rich clots.^{12 13} These contrasting results probably resulted from the variable concentrations of platelets, t-PA, PAI-1, and other factors that were used in different in vitro experiments. However, the concentrations of fibrinolytic components at sites of arterial injury are not well defined.¹⁴ Therefore, in vivo experiments are necessary to examine the true function of PAI-1 in regulating thrombolysis at sites of arterial injury. The capacity to manipulate the mouse genome by gene targeting approaches has provided a powerful tool for studying protein function in vivo.^{15 16} Mice lacking PAI-1 have been genetically engineered,¹⁷ and these animals exhibit a phenotype consistent with that observed in humans with PAI-1 deficiency.^{18 19} To address the role of PAI-1 in the regulation of arterial thrombolysis, we developed a murine model of arterial injury and thrombosis and used it to study both wild-type and PAI-1–deficient mice.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals
C57BL/6J mice were purchased from Jackson Laboratory, Bar Harbor, Me. PAI-1–deficient mice were generated by homologous recombination in embryonic stem cells, as described previously.¹⁷ To eliminate potential effects of strain differences on experimental results, consecutive generations of mice carrying the null PAI-1 allele were backcrossed repeatedly to C57BL/6J mice. Only mice that were the product of five or more backcrosses to C57BL/6J were used in experiments comparing PAI-1–deficient (PAI-1 -/-) mice with wild-type C57BL/6J (PAI-1 +/+) mice. Genotyping of mice was performed by polymerase chain reaction analysis of tail DNA as described previously.²⁰ All animal care and experimental procedures complied with The Guide for Care and Use of Laboratory Animals, Department of Health, Education, and Welfare Publication No. NIH 78-23, and were approved by the University of Michigan Committee on Use and Care of Animals.

Thrombosis Protocol
Mice (6 to 8 weeks old; weight, 25 g) were anesthetized by inhalation of 1% isoflurane and secured in the supine position under a dissecting microscope (Zeiss). A midline cervical incision was made, and the left common carotid artery was isolated by blunt dissection. FeCl₃ (Mallinckrodt Chemical) was used to induce vascular injury.²¹ A 1x2-mm strip of filter paper saturated with 10% FeCl₃ solution was applied to the adventitial surface of the surgically exposed carotid artery for 3.0 minutes, then removed. The surgical incision was sutured with 4–0 monofilament, and the animal was returned to its cage. Operators were blinded to PAI-1 genotype while performing the thrombosis protocol. Twenty-four hours later, mice were anesthetized, and the injured carotid segments were isolated and perfusion-fixed by manual injection of 4% formaldehyde (1.0 mL) into the heart via a 25-gauge needle. The injured carotid artery segment and 1 mm of proximal and 1 mm of distal uninjured artery were excised (total length of excised arterial segment, 4 mm), placed in formaldehyde fixative, and later embedded in paraffin for histological analyses.

Histological and Morphometric Analyses
To quantify the amount of thrombus present in carotid arteries 24 hours after injury, four evenly spaced transverse sections (distance between sections, 1 mm) were prepared from each paraffin-embedded carotid artery and subjected to hematoxylin-eosin staining. Each transverse section was scored for the presence or absence of intraluminal thrombus. In addition, a computer-assisted planimetry program (Image-Pro Plus, Media Cybernetics) was used to measure the cross-sectional area of thrombus for each transverse section, and the mean of these values was calculated for each artery. Examiners were blinded to the genotype (ie, PAI-1 +/+ or -/-) of specimens during all histological analyses. To determine the composition of thrombi, some carotid artery specimens were analyzed by transmission electron microscopy as described previously.²²

Platelet Aggregation Studies
Blood was collected into citrate anticoagulant from anesthetized mice by inferior vena cava puncture with a 25-gauge needle. PRP was prepared by centrifuging blood (120g for 6 minutes) at room temperature in a swing-out rotor. The platelet count of PRP was adjusted with citrated platelet-poor plasma to 2x10⁸ platelets/mL. Samples (200 µL) of PRP were placed in 7.5x55-mm siliconized flat-bottom tubes, and standard aggregometry was performed with a model PAP-4 aggregometer (Bio/Data Corp).

Statistical Analyses
Data are presented as mean±SD. The generalized estimating equations method was used to determine whether a significant difference existed between experimental groups in the prevalence of intraluminal thrombus.²³ The Wilcoxon rank-sum test was used to determine whether a significant difference existed in mean thrombus cross-sectional areas between experimental groups. Student's unpaired t test was used to compare in vitro aggregation of wild-type and PAI-1–deficient platelets.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Murine Model of Acute Arterial Injury
We performed a series of studies to determine the feasibility of using mice to study arterial thrombosis and thrombolysis. The common carotid artery was selected for analysis because it was easily approached via a midline cervical incision. After performing the procedure on 3 to 5 mice, operators could routinely isolate the carotid artery in <10 minutes. We used topical application of FeCl₃ to the exposed carotid artery to induce vascular injury and thrombosis.²¹ Completely occlusive carotid artery thrombosis was well tolerated by mice, presumably because of collateral cerebral blood flow provided by the contralateral carotid artery. After recovery from anesthesia, mice appeared healthy, demonstrating normal ambulation, feeding, and grooming. The operative mortality rate of carotid artery surgery was <5%. Fig 1 demonstrates the use of Whatman 1 filter paper to apply FeCl₃ to the arterial surface. Control experiments performed in >50 wild-type mice revealed that 10% FeCl₃ induced completely occlusive thrombosis within 30 minutes (determined by visual inspection of the artery under the dissecting microscope) in >90% of mice, whereas application of filter paper alone (ie, no FeCl₃) to carotid arteries did not induce thrombosis. To determine the composition of thrombi induced by FeCl₃, injured carotid artery segments were perfusion-fixed immediately after induction of thrombosis, excised, and examined histologically. Light microscopic analysis of hematoxylin-eosin–stained specimens from 10 consecutive mice revealed that thrombus composition was uniform from animal to animal (Fig 2A). Transmission electron microscopy confirmed that thrombi consisted predominantly of dense platelet aggregates (Fig 2B), consistent with the composition of arterial thrombi observed in humans and large-animal thrombosis models.

View larger version (90K): [in this window] [in a new window]   Figure 1. Induction of vascular injury in murine carotid artery. A 1x2-mm strip of filter paper saturated with 10% FeCl3 was applied to surface of surgically exposed left carotid artery for 3 minutes, as described in "Methods." Forceps elevate carotid artery, which is viewed through a dissecting microscope (magnification x16).

View larger version (102K): [in this window] [in a new window]   Figure 2. Histological analysis of acute carotid artery thrombi. A, Light microscopy. Platelet-rich, occlusive thrombus is observed (hematoxylin-eosin stain, magnification x20). B, Transmission electron microscopy. Thrombus within lumen of artery is composed predominantly of platelets. Note serpiginous internal elastic lamina, covered by single layer of endothelial cells (lead citrate–uranyl acetate stain, magnification x3400).

Application of Carotid Injury Model to PAI-1–Deficient Mice
To examine the role of PAI-1 in regulating endogenously mediated arterial thrombolysis, we applied the FeCl₃ model to wild-type (PAI-1 +/+) and PAI-1–deficient (PAI-1 -/-) mice. Twenty-two PAI-1 +/+ and 14 age- and sex-matched PAI-1 -/- mice were studied. Each group was subjected to identical carotid artery injury with 10% FeCl₃ as described in "Methods." There was no difference in operative bleeding between the two experimental groups. Twenty-four hours later, the injured carotid segments were perfusion-fixed and excised. Examiners were blinded to PAI-1 genotype during all evaluations of tissue samples. To determine whether the amount of residual intraluminal thrombus differed between experimental groups, each segment of injured carotid artery was cross-sectioned at four evenly spaced intervals as described in "Methods," and transverse sections were prepared for histological analysis (Fig 3). Residual thrombus (either completely or partially occlusive) was detected in 55 of 85 sections (64.7%) obtained from PAI-1 +/+ mice, compared with 19 of 56 sections (33.9%) from PAI-1 -/- mice (P=.009, Fig 4A). The cross-sectional area of thrombus was measured for each transverse section by computer-assisted planimetry, and the mean thrombus area for each artery was calculated (Fig 4B). Mean residual thrombus area was 0.033±0.027 mm² (95% CI, 0.022 to 0.044 mm²) in PAI-1 +/+ mice versus 0.016±0.015 mm² (95% CI, 0.008 to 0.024 mm²) in PAI-1 -/- mice (P=.048). Subgroup analysis of patent and occluded vessels revealed an equal proportion of patent arteries in both groups (9 of 22 PAI-1 +/+ mice versus 6 of 14 PAI-1 -/- mice). However, significantly less residual mural thrombus was observed in patent vessels from PAI-1 -/- mice than in those from PAI-1 +/+ mice (0.001±0.002 versus 0.011±0.015 mm², respectively, P<.05). Similarly, increased thrombus was present in occluded vessels from PAI-1 +/+ mice compared with PAI-1 -/- mice (0.052±0.021 versus 0.027±0.010 mm², respectively, P<.05).

View larger version (57K): [in this window] [in a new window]   Figure 3. Transverse sections of carotid arteries 24 hours after FeCl3 injury. A, PAI-1 +/+ mouse. B, PAI-1 -/- mouse. Note noncircumferential, full-thickness arterial injury induced by FeCl3 (hematoxylin-eosin stain, magnification x20).

View larger version (25K): [in this window] [in a new window]   Figure 4. Effect of PAI-1 on arterial thrombolysis. Carotid arteries of PAI-1 +/+ (n=22) and PAI-1 -/- (n=14) mice were harvested 24 hours after 10% FeCl3 injury. Four evenly spaced transverse sections were prepared from each artery and analyzed histologically. A, Prevalence of transverse sections containing intraluminal thrombus. B, Mean thrombus cross-sectional area within all, occluded, and patent arteries. Occluded vessels were defined as those in which 1 transverse section demonstrated complete filling of lumen with thrombus. Error bars represent 95% CIs. *P<.05, **P <.01 vs PAI-1 +/+ mice.

The significant difference in residual thrombus observed between wild-type and PAI-1–deficient mice 24 hours after injury could be explained by reduced thrombus formation and/or by enhanced thrombolysis in PAI-1 -/- mice. To address this issue, we studied thrombus generation after vascular injury in PAI-1 +/+ (n=8) and PAI-1 -/- (n=4) mice. Mice were subjected to arterial injury with 10% FeCl₃ for 3 minutes. Thereafter, a miniature Doppler flow probe (model 0.5VB, Transonic Systems) that interfaced with a Transonic model T106 flowmeter was applied to the carotid artery, and blood flow was recorded with a computerized data acquisition program (WinDaq, DATAQ Instruments). All 4 vessels of PAI-1 -/- mice occluded within 30 minutes of initiation of injury, whereas 7 of 8 vessels from PAI-1 +/+ mice occluded within 30 minutes. These results suggested that PAI-1 -/- mice did not exhibit a major defect in thrombus formation after injury compared with PAI-1 +/+ mice. Because several minutes were necessary to properly position the flow probe on the artery, precise determination of the time of arterial occlusion was not possible in 7 of 12 mice studied, because the vessel had already thrombosed by the time the flow probe was properly positioned. Recorded times to occlusion after initiation of injury were <7.5, <9.5, 15.5, and 21 minutes in PAI-1 -/- mice versus <6.0, <6.5, <8.5, <15, <15, 17, and 16 minutes in PAI-1 +/+ mice (blood flow was monitored for a total of 45 minutes after injury in the 1 PAI-1 +/+ animal that did not develop occlusive carotid artery thrombosis). To determine whether PAI-1 deficiency was associated with a primary defect in platelet aggregation, pooled platelet-rich plasma was prepared from PAI-1 +/+ mice (n=2) and PAI-1 -/- mice (n=2), and in vitro platelet aggregation studies were performed (Fig 5). There was no significant difference in ADP-induced aggregation between PAI-1 +/+ and PAI-1 -/- platelets (64.5±4.9% in PAI-1 +/+ mice versus 58±4.2% in PAI-1 -/- mice, P=.29). We also compared thrombus composition in PAI-1 +/+ and PAI-1 -/- mice, because this parameter is an important determinant of the rate of clot lysis.²⁴ No gross differences were observed—ie, all thrombi appeared to be platelet-rich. Because leukocytes migrate into thrombi within 24 hours after initial formation and leukocyte proteases, such as elastase, degrade fibrin,^{3 25} we compared thrombus leukocyte density between experimental groups. No significant differences were observed (1.4±0.4 leukocytes per high-power field in PAI-1 +/+ mice versus 1.4±0.4 leukocytes per high-power field in PAI-1 -/- mice). Similarly, no differences in the histological appearance of injured arterial walls was observed between PAI-1 +/+ and PAI-1 -/- mice. Topical application of FeCl₃ produced full-thickness, noncircumferential vascular injury (Fig 3). Medial cross-sectional area, an index of the severity of vessel injury, did not differ between groups (0.015±0.0026 mm² in PAI-1 +/+ mice versus 0.015±0.0041 mm² in PAI-1 -/- mice).

View larger version (82K): [in this window] [in a new window]   Figure 5. Aggregation of PAI-1 +/+ and PAI-1 -/- platelets. Pooled PRP prepared from PAI-1 +/+ (n=2) and PAI-1 -/- (n=2) mice was aggregated by addition of ADP (20 µmol/L).

Modification of Injury Model for Study of Thrombus Formation
Our experiments with the vascular flow probe suggested that the carotid artery model would prove useful for quantitatively studying blood flow and thrombus formation in mice. Such a system would be useful in the analysis of mice with genetic modifications in factors that regulate carotid artery blood flow (eg, adrenergic receptors) or platelet deposition after arterial injury (eg, platelet or endothelial cell integrins). Carotid artery blood flow in anesthetized mice (n=14) was 1.1±0.7 mL/min. Mice could be maintained under general anesthesia for at least 1 hour with stable heart and respiratory rates and stable carotid artery blood flows. As shown in Fig 6A, high-quality flow tracings could be obtained from the mouse carotid artery. To better study thrombosis after injury, we modified our protocol to allow induction of vascular injury while the flow probe was positioned on the artery. This was done with a smaller strip of filter paper (0.5x1.0 mm) saturated with higher concentrations of FeCl₃ (25% to 50%) applied proximal to the flow probe. Mean time to occlusion was 13.6±5.1 minutes after 25% FeCl₃ injury (n=4) and 5.6±4.9 minutes after 50% FeCl₃ injury (n=5). Cyclic flow reductions, which result from repetitive formation and embolization of thrombi at sites of vascular injury,²⁶ were observed (Fig 6B). These observations indicate that the carotid artery model demonstrates several features observed in large-animal models and therefore should prove useful in murine studies of blood flow regulation and thrombosis after vascular injury.

View larger version (39K): [in this window] [in a new window]   Figure 6. Monitoring of carotid artery blood flow. Miniature Doppler flow probe (7.2 MHz) was used to monitor carotid artery blood flow in mice. A, Phasic carotid artery flow before and after FeCl3 injury. B, Mean carotid artery blood flow in different mouse subjected to FeCl3 injury (50%) for 1.5 minutes. Artifactual reduction in flow during induction of injury is due to removal of saline from surgical site to allow application of FeCl3. Note that mean blood flow initially declines gradually and that repetitive, transient increases in flow are observed. Thereafter, flow declines rapidly, with complete loss of flow occurring 14 minutes after injury. After loss of flow in left carotid artery was documented, flow probe was placed on right carotid artery. Flow rate of 1.6 mL/min was observed (data not shown).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Platelet-rich thrombi are more resistant to lysis by t-PA than platelet-poor thrombi.²⁴ However, the mechanisms underlying this phenomenon are not well defined. In this report, we studied the role of PAI-1 in regulating the endogenous clearance of platelet-rich arterial thrombi in mice. PAI-1 is abundant in platelets, and its secretion from vascular endothelial cells is stimulated by factors released from activated platelets.²⁷ Several in vitro studies suggest that PAI-1 is the dominant factor underlying platelet-mediated clot lysis resistance.^{7 8 10 11} However, other studies have concluded that PAI-1 plays only a minor role in inhibiting the lysis of platelet-rich clots.^{12 13} These discordant results are probably explained by the different concentrations of t-PA and platelets that were used in different in vitro studies, which do not necessarily reflect those attained in vivo at sites of arterial injury. Furthermore, in vitro experiments do not account for the role of the vascular wall in the regulation of clot lysis. Earlier studies examining the role of PAI-1 in regulating clot lysis in vivo involved the injection of preformed clots into veins or the injection of whole blood/thrombin mixtures into isolated arterial segments.^{7 28 29 30 31} Therefore, the role of PAI-1 in regulating the clearance of platelet-rich thrombi that form in response to arterial injury has not been adequately addressed. Our study has demonstrated that compared with wild-type mice, mice lacking PAI-1 exhibit a significant reduction in intraluminal thrombus 24 hours after arterial injury. These results suggest that PAI-1 inhibits the lysis of platelet-rich thrombi that form in vivo in response to arterial injury and are consistent with our earlier studies demonstrating that in vitro clots containing human PAI-1–deficient platelets lyse more rapidly than clots with normal PAI-1 content.³² In addition to delaying restoration of blood flow in occluded arteries, inhibition of arterial thrombolysis by PAI-1 would be expected to retard clearance of nonocclusive mural thrombi. Mural arterial thrombi appear to contribute to the development of atherosclerosis, because they may be incorporated into developing lesions or serve as a source of platelet-derived growth factors that stimulate smooth muscle cell proliferation.³³ Therefore, our results are consistent with the recent report that PAI-1 deficiency protects apolipoprotein E–deficient mice from the development of atherosclerosis.³⁴ Although the results of murine studies must be extended with caution to human diseases, our studies relate to the variable thrombolysis that is observed in humans with acute coronary artery occlusion. It is not well understood why spontaneous thrombolysis is observed in some individuals but not in others. Plasma PAI-1 concentrations vary widely in the normal population,^{35 36} which may account, at least partially, for the variable degree of endogenous thrombolysis that is observed after arterial thrombosis in humans.

Detection of less residual thrombus after injury in PAI-1 -/- mice does not necessarily imply enhanced thrombolysis compared with PAI-1 +/+ mice, because it was not possible in our study to confirm equal amounts of thrombus deposition in each group. However, studies in which a flow probe was used to confirm thrombus formation did not suggest a diminished tendency to form thrombi in PAI-1 -/- mice. In addition, in vitro studies revealed no significant difference in platelet aggregation between experimental groups. Similarly, histological analysis of injured carotid segments did not reveal differences in thrombus composition or the extent of injury between groups. Carmeliet et al³⁰ demonstrated that PAI-1 -/- mice exhibit normal tail bleeding times and normal blood loss after amputation of the caecum compared with PAI-1 +/+ mice. Together, these observations suggest that there is no significant difference in clot formation after injury between PAI-1 +/+ and PAI-1 -/- mice and that the reduction in residual thrombus that we observed 24 hours after injury in PAI-1 -/- mice resulted from enhanced thrombolysis. However, because thrombosis and thrombolysis can occur concurrently in vivo,⁷ it is possible that diminished thrombus formation also contributed to our results. Regardless of mechanism, our studies demonstrate the important role of PAI-1 in determining the net amount of platelet-rich thrombus present in arteries after injury.

Characterization of FeCl₃-Induced Thrombosis and Comparison With Other Models
In addition to studying the biological function of PAI-1, a goal of our study was to develop a reliable model of arterial injury and thrombosis in mice. Kurz et al²¹ first described the use of FeCl₃ to induce arterial thrombosis in rats weighing 375 to 450 g. Our studies demonstrate that this method can be applied effectively to animals weighing <25 g and that FeCl₃ produces platelet-rich thrombi. The FeCl₃ model exhibits several features that suggest that it will prove useful for studying the molecular determinants of arterial thrombosis and thrombolysis in transgenic mice. It allows for uniform injury from animal to animal, because the concentration of FeCl₃, the size of the arterial segment being injured, and the duration of injury can be precisely controlled. Because FeCl₃ does not produce circumferential vessel injury, it allows induction of thrombosis without complete destruction of vascular cells that mediate subsequent thrombolysis. Carotid artery blood flow can be monitored accurately in mice, and complete vascular occlusion is well tolerated because of collateral blood flow. In addition, the relevance of the murine model to large-animal thrombosis models is supported by the fact that cyclic flow variations are observed in the mouse carotid artery after FeCl₃ injury.²⁶ A variety of methods have been used to study thrombosis in rodents. These include application of electrical, mechanical, and other forms of energy to different vascular sites, intravenous injection of clots formed in vitro, and injection of blood/thrombin mixtures into isolated vascular segments.^{31 37 38 39 40 41 42} Only a few of these models have been applied to mice. Carmeliet et al³⁰ and Palabrica et al⁴³ modified the hamster pulmonary embolism model of Stassen et al³⁷ to study the regulation of thrombolysis in mice, whereas Pierangeli⁴⁴ used "pinch" injury to induce femoral vein thrombosis. In contrast to these experimental systems, our model includes the key components of arterial injury and high-velocity laminar flow that are necessary to generate platelet-rich thrombi. The mechanism by which FeCl₃ induces thrombosis is not well defined. Iron induces formation of highly reactive oxidant species and potentiates the sensitivity of endothelial cells to oxidant damage.⁴⁵ Recent studies indicate that FeCl₃ induces thrombosis by triggering expression of tissue factor, a major determinant of thrombosis at sites of atherosclerotic plaque rupture.^{46 47} Carmeliet et al⁴⁸ used perivascular electric injury to study vascular wound healing and neointima formation in mouse femoral arteries. Induction of thrombi by electrical injury may depend on the generation of reactive iron species, because only iron-containing electrodes efficiently cause thrombus formation.²¹ Therefore, it is possible that topical FeCl₃ and electrical current delivered by iron-containing electrodes induce vascular injury by similar mechanisms.

In summary, we have developed a murine model of carotid artery injury that we have used to demonstrate the important role of PAI-1 in regulating the acute clearance of arterial, platelet-rich thrombi. The model is easy to perform and does not require the use of specialized surgical techniques or equipment to induce vascular injury. Because many other components of the murine blood coagulation and fibrinolytic systems have been modified by gene targeting approaches,^{49 50 51 52 53 54 55} this model should prove useful for studying the function of other blood coagulation and fibrinolysis factors within the distinct environment of the acutely injured artery.

	Selected Abbreviations and Acronyms

 

PAI-1 = plasminogen activator inhibitor-1 PRP = platelet-rich plasma t-PA = tissue plasminogen activator u-PA = urokinase plasminogen activator

	Acknowledgments

 
This work was supported in part by National Institutes of Health grants HL-02728 (Dr Fay) and HL-07853–01 (Dr Farrehi) and by American Heart Association, Michigan Affiliate, Fellowship Award 26F967 (Dr Farrehi). We are grateful to Drs Tom Wakefield and Benedict Lucchesi for sharing laboratory equipment, Randy Westrick and Andrew Parker for technical assistance, and Jennifer Sievers for statistical assistance. We also thank Dr David Gordon, Chris Edwards, and Lingling Xu for assistance with tissue preparation and histological analyses. Finally, we thank Dr David Ginsburg for critically reviewing the manuscript.

	Footnotes

 
Reprint requests to William P. Fay, MD, University of Michigan Medical Center, MSRB III Room 7301, 1150 W Medical Center Dr, Ann Arbor, MI 48109-0644.

Received July 17, 1997; revision received October 2, 1997; accepted October 21, 1997.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126–2146.[Abstract/Free Full Text]

2. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78:3114–3124.[Free Full Text]

3. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897–902.[Abstract]

4. Boehrer JD, Glamann DB, Lange RA, Willard JE, Brogan WC, Eichhorn EJ, Grayburn PA, Anwar A, Hillis LD. Effect of coronary angioplasty on late potentials one to two weeks after acute myocardial infarction. Am J Cardiol. 1992;70:1515–1519.[Medline] [Order article via Infotrieve]

5. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation. 1995;91:1923–1928.[Abstract/Free Full Text]

6. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J. 1995;9:939–945.[Abstract]

7. Levi M, Biemond BJ, van Zonneveld AJ, Wouter Ten Cate J, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 1992;85:305–312.[Abstract/Free Full Text]

8. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res. 1993;72:413–421.[Medline] [Order article via Infotrieve]

9. Torr-Brown SR, Sobel BE. Plasminogen activator inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus. Thromb Res. 1994;75:473–477.[Medline] [Order article via Infotrieve]

10. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor-1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombosis. Blood. 1993;81:1290–1299.[Abstract/Free Full Text]

11. Stringer HAR, van Sweiten P, Heijnen H, Sixma J, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Arterioscler Thromb. 1994;14:1452–1458.[Abstract/Free Full Text]

12. Kunitada S, Fitzgerald G, Fitzgerald D. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood. 1992;79:1420–1427.[Abstract/Free Full Text]

13. Bajzar L, Tracy PB. Platelet factor V(a) is responsible for the majority of the antifibrinolytic effect of platelets. Blood. 1995;86:74a. Abstract.

14. Fay WP, Murphy JG, Owen WG. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi. Arterioscler Thromb Vasc Biol. 1996;16:1277–1284.[Abstract/Free Full Text]

15. Doevendans PA, Hunter JJ, Lembo G, Wollert KC, Chien KR. Strategies for studying cardiovascular diseases in transgenic and gene-targeted mice. In: Monastersky GM, Robl JM, eds. Strategies in Transgenic Animal Science. Washington, DC: American Society for Microbiology; 1995:107–144.

16. Chien KR. Molecular medicine in genetically engineered animals: series introduction. J Clin Invest. 1996;98(suppl):S1.

17. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan R. Plasminogen activator inhibitor-1 gene deficient mice, I: generation by homologous recombination and characterization. J Clin Invest. 1993;92:2746–2755.

18. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen activator inhibitor type-1 due to a frame-shift mutation. N Engl J Med. 1992;327:1729–1733.[Medline] [Order article via Infotrieve]

19. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 1997;90:204–208.[Abstract/Free Full Text]

20. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996;97:232–237.[Medline] [Order article via Infotrieve]

21. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thrombosis Res. 1990;60:269–280.[Medline] [Order article via Infotrieve]

22. Hayat MA. Principles and Techniques of Electron Microscopy. Boca Raton, Fla: CRC Press; 1989.

23. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13–22.[Abstract/Free Full Text]

24. Jang I, Gold H, Ziskind A, Fallon J, Holt R, Leinbach R, May J, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation. 1989;79:920–928.[Abstract/Free Full Text]

25. Henry RL. Leukocytes and thrombosis. Thromb Diath Haemorrhagica. 1965;13:35–46.[Medline] [Order article via Infotrieve]

26. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation. 1991;83(suppl IV):IV-3-IV-14.

27. Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation. 1990;82:1485–1493.[Abstract/Free Full Text]

28. Reilly CF, Fujita T, Mayer EJ, Siegfried ME. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. Arterioscler Thromb. 1991;11:1276–1286.[Abstract/Free Full Text]

29. Marsh JJ, Konopka RG, Lang IM, Wang HY, Pedersen C, Chiles P, Reilly CF, Moser KM. Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation. 1994;90:3091–3097.[Abstract/Free Full Text]

30. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice, II: effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993;92:2756–2760.

31. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation. 1995;91:1175–1181.[Abstract/Free Full Text]

32. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 dependent and independent mechanisms. Blood. 1994;83:351–356.[Abstract/Free Full Text]

33. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]

34. Eitzman DT, Nabel EG, Gordon D, Fay WP, Rekhter MD, Ginsburg D. Atherosclerosis in transgenic mice that either overexpress or lack the murine plasminogen activator inhibitor-1 gene. Circulation. 1996;94(suppl I):I-460. Abstract.

35. Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor-1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood. 1987;70:1645–1653.[Abstract/Free Full Text]

36. Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res. 1984;33:523–530.[Medline] [Order article via Infotrieve]

37. Stassen JM, Lijnen HR, Kieckens L, Collen D. Small animal thrombosis models for the evaluation of thrombolytic agents. Circulation. 1991;83:65–79.

38. Philip RB, Francey I, Warren BA. Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis. Haemostasis. 1978;7:282–293.[Medline] [Order article via Infotrieve]

39. Weichert W, Breddin HK. Effect of antibiotics on laser-induced thrombus formation in rat mesenteric arterioles. Haemostasis. 1989;19:224–228.[Medline] [Order article via Infotrieve]

40. Matsuno H, Uematsu T, Nagashima S, Nakashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods. 1991;25:303–317.[Medline] [Order article via Infotrieve]

41. Davidson SF, Brantley SK, Talbot PJ, Das SK. A functional model of microvascular thrombosis. Plast Reconstr Surg. 1990;86:579–581.[Medline] [Order article via Infotrieve]

42. Lenfors S, Marberg L, Wikstrom S, Jonsson U, Eriksson AW, Gustafsson D. A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition. Blood Coagul Fibrinolysis. 1993;4:263–271.[Medline] [Order article via Infotrieve]

43. Palabrica T, Liu A, Aronovitz M, Furie B, Lawn R. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med. 1995;1:256–259.[Medline] [Order article via Infotrieve]

44. Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Harris EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost. 1994;71:670–674.[Medline] [Order article via Infotrieve]

45. Balla G, Vercellotti GM, Eaton JW, Jacob HS. Iron loading of endothelial cells augments oxidant damage. J Lab Clin Med. 1990;116:546–554.[Medline] [Order article via Infotrieve]

46. Rote WE, Oldeschulte GL, Dempsey EM, Vlasuk GP. Evaluation of a novel small protein inhibitor of the blood coagulation factor VIIa/tissue factor complex in animal models of arterial and venous thrombosis. Circulation. 1996;94(suppl I):I-695. Abstract.

47. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594–599.[Abstract/Free Full Text]

48. Carmeliet P, Moons L, Stassen JM, De Mol M, Bouche A, van den Oord JJ, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol. 1997;150:761–776.[Abstract]

49. Carmeliet P, Collen D. Evaluation of the plasminogen/plasmin system in transgenic mice. Fibrinolysis. 1994;8:269–276.

50. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 1995;9:794–807.[Abstract/Free Full Text]

51. Bugge TH, Suh TT, Flick MJ, Daugherty CC, Romer J, Solberg H, Ellis V, Dano K, Degen JL. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem. 1995;270:16886–16894.[Abstract/Free Full Text]

52. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci U S A. 1995;92:12426–12430.[Abstract/Free Full Text]

53. Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell. 1990;62:447–456.[Medline] [Order article via Infotrieve]

54. Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter SS, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995;9:2020–2033.[Abstract/Free Full Text]

55. Ploplis V, Carmeliet P, Vazirzadeh S, Vlaenderen IV, Moons L, Plow E, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 1995;92:2585–2593.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. W. Miller, S. Basra, D. W. Kulp, P. C. Billings, S. Choi, M. P. Beavers, O. J. T. McCarty, Z. Zou, M. L. Kahn, J. S. Bennett, et al. Small-molecule inhibitors of integrin {alpha}2{beta}1 that prevent pathological thrombus formation via an allosteric mechanism PNAS, January 20, 2009; 106(3): 719 - 724. [Abstract] [Full Text] [PDF]

				D.J.W. Evans, L.E. Jackman, J. Chamberlain, D.J. Crosdale, H.M. Judge, K. Jetha, K.E. Norman, S.E. Francis, and R.F. Storey Platelet P2Y12 Receptor Influences the Vessel Wall Response to Arterial Injury and Thrombosis Circulation, January 6, 2009; 119(1): 116 - 122. [Abstract] [Full Text] [PDF]

				P. F. Bodary Links Between Adipose Tissue and Thrombosis in the Mouse Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2284 - 2291. [Abstract] [Full Text] [PDF]

				R. J. Westrick, M. E. Winn, and D. T. Eitzman Murine Models of Vascular Thrombosis Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2079 - 2093. [Abstract] [Full Text] [PDF]

				S. M. Kuchay, N. Kim, E. A. Grunz, W. P. Fay, and A. H. Chishti Double Knockouts Reveal that Protein Tyrosine Phosphatase 1B Is a Physiological Target of Calpain-1 in Platelets Mol. Cell. Biol., September 1, 2007; 27(17): 6038 - 6052. [Abstract] [Full Text] [PDF]

				W. P. Fay, N. Garg, and M. Sunkar Vascular Functions of the Plasminogen Activation System Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1231 - 1237. [Abstract] [Full Text] [PDF]

				U. J.H. Sachs and B. Nieswandt In Vivo Thrombus Formation in Murine Models Circ. Res., April 13, 2007; 100(7): 979 - 991. [Abstract] [Full Text] [PDF]

				G. J. Oostingh, M. Pozgajova, R. J. Ludwig, T. Krahn, W.-H. Boehncke, B. Nieswandt, and M. P. Schon Diminished thrombus formation and alleviation of myocardial infarction and reperfusion injury through antibody- or small-molecule-mediated inhibition of selectin-dependent platelet functions Haematologica, April 1, 2007; 92(4): 502 - 512. [Abstract] [Full Text] [PDF]

				C. V. Denis and D. D. Wagner Platelet Adhesion Receptors and Their Ligands in Mouse Models of Thrombosis Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 728 - 739. [Abstract] [Full Text] [PDF]

				J. Liu, M. E. C. Fitzgerald, M. C. Berndt, C. W. Jackson, and T. K. Gartner Response: Establishing the physiological significance in vivo answers the challenge of unraveling the details of GPIb-initiated signal transduction Blood, January 15, 2007; 109(2): 847 - 848. [Full Text] [PDF]

				J. Liu, M. E. Fitzgerald, M. C. Berndt, C. W. Jackson, and T. K. Gartner Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo Blood, October 15, 2006; 108(8): 2596 - 2603. [Abstract] [Full Text] [PDF]

				S. Zaitsev, K. Danielyan, J.-C. Murciano, K. Ganguly, T. Krasik, R. P. Taylor, S. Pincus, S. Jones, D. B. Cines, and V. R. Muzykantov Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis Blood, September 15, 2006; 108(6): 1895 - 1902. [Abstract] [Full Text] [PDF]

				M. Rucker, T. Schafer, C. Scheuer, Y. Harder, B. Vollmar, and M. D. Menger Local Heat Shock Priming Promotes Recanalization of Thromboembolized Microvasculature by Upregulation of Plasminogen Activators Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1632 - 1639. [Abstract] [Full Text] [PDF]

				S. Falati, S. Patil, P. L. Gross, M. Stapleton, G. Merrill-Skoloff, N. E. Barrett, K. L. Pixton, H. Weiler, B. Cooley, D. K. Newman, et al. Platelet PECAM-1 inhibits thrombus formation in vivo Blood, January 15, 2006; 107(2): 535 - 541. [Abstract] [Full Text] [PDF]

				J. K. Hennan, H. Elokdah, M. Leal, A. Ji, G. S. Friedrichs, G. A. Morgan, R. E. Swillo, T. M. Antrilli, A. Hreha, and D. L. Crandall Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 710 - 716. [Abstract] [Full Text] [PDF]

				V. M Silva, N. Corson, A. Elder, and G. Oberdorster The Rat Ear Vein Model for Investigating In Vivo Thrombogenicity of Ultrafine Particles (UFP) Toxicol. Sci., June 1, 2005; 85(2): 983 - 989. [Abstract] [Full Text] [PDF]

				M. D. Iafrati, O. Vitseva, K. Tanriverdi, P. Blair, S. Rex, S. Chakrabarti, S. Varghese, and J. E. Freedman Compensatory mechanisms influence hemostasis in setting of eNOS deficiency Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1627 - H1632. [Abstract] [Full Text] [PDF]

				K. Shim, H. Zhu, L. A. Westfield, and J. E. Sadler A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury Blood, July 15, 2004; 104(2): 415 - 419. [Abstract] [Full Text] [PDF]

				F. A. Jaffer, C.-H. Tung, J. J. Wykrzykowska, N.-H. Ho, A. K. Houng, G. L. Reed, and R. Weissleder Molecular Imaging of Factor XIIIa Activity in Thrombosis Using a Novel, Near-Infrared Fluorescent Contrast Agent That Covalently Links to Thrombi Circulation, July 13, 2004; 110(2): 170 - 176. [Abstract] [Full Text] [PDF]

				B. Kerlin, B. C. Cooley, B. H. Isermann, I. Hernandez, R. Sood, M. Zogg, S. B. Hendrickson, M. W. Mosesson, S. Lord, and H. Weiler Cause-effect relation between hyperfibrinogenemia and vascular disease Blood, March 1, 2004; 103(5): 1728 - 1734. [Abstract] [Full Text] [PDF]

				K. Schafer, K. Muller, A. Hecke, E. Mounier, J. Goebel, D. J. Loskutoff, and S. Konstantinides Enhanced Thrombosis in Atherosclerosis-Prone Mice Is Associated With Increased Arterial Expression of Plasminogen Activator Inhibitor-1 Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2097 - 2103. [Abstract] [Full Text] [PDF]

				N. V. Gorlatova, H. Elokdah, K. Fan, D. L. Crandall, and D. A. Lawrence Mapping of a Conformational Epitope on Plasminogen Activator Inhibitor-1 by Random Mutagenesis. IMPLICATIONS FOR SERPIN FUNCTION J. Biol. Chem., April 25, 2003; 278(18): 16329 - 16335. [Abstract] [Full Text] [PDF]

				F. A. Jaffer, C.-H. Tung, R. E. Gerszten, and R. Weissleder In Vivo Imaging of Thrombin Activity in Experimental Thrombi With Thrombin-Sensitive Near-Infrared Molecular Probe Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1929 - 1935. [Abstract] [Full Text] [PDF]

				K. Schafer, S. Konstantinides, C. Riedel, T. Thinnes, K. Muller, C. Dellas, G. Hasenfuss, and D. J. Loskutoff Different Mechanisms of Increased Luminal Stenosis After Arterial Injury in Mice Deficient for Urokinase- or Tissue-Type Plasminogen Activator Circulation, October 1, 2002; 106(14): 1847 - 1852. [Abstract] [Full Text] [PDF]

				T. Chavakis, R. A. Pixley, I. Isordia-Salas, R. W. Colman, and K. T. Preissner A Novel Antithrombotic Role for High Molecular Weight Kininogen as Inhibitor of Plasminogen Activator Inhibitor-1 Function J. Biol. Chem., August 30, 2002; 277(36): 32677 - 32682. [Abstract] [Full Text] [PDF]

				J. N. Lorenz A practical guide to evaluating cardiovascular, renal, and pulmonary function in mice Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1565 - R1582. [Abstract] [Full Text] [PDF]

				L. Peng, N. Bhatia, A. C. Parker, Y. Zhu, and W. P. Fay Endogenous Vitronectin and Plasminogen Activator Inhibitor-1 Promote Neointima Formation in Murine Carotid Arteries Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 934 - 939. [Abstract] [Full Text] [PDF]

				A. Manganaro, M. Ruggeri, G. Ando, M. Longo, and G. Vita Endothelial Functions in Pathophysiology of Thrombosis and Fibrinolysis: Late Spontaneous Recanalization of an Occluded Internal Carotid Artery: A Case Report Angiology, January 1, 2002; 53(1): 99 - 103. [Abstract] [PDF]

				M. B. DeYoung, C. Tom, and D. A. Dichek Plasminogen Activator Inhibitor Type 1 Increases Neointima Formation in Balloon-Injured Rat Carotid Arteries Circulation, October 16, 2001; 104(16): 1972 - 1971. [Abstract] [Full Text] [PDF]

				H. Weiler, V. Lindner, B. Kerlin, B. H. Isermann, S. B. Hendrickson, B. C. Cooley, D. A. Meh, M. W. Mosesson, N. W. Shworak, M. J. Post, et al. Characterization of a Mouse Model for Thrombomodulin Deficiency Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1531 - 1537. [Abstract] [Full Text] [PDF]

				Y. Zhu, P. M. Farrehi, and W. P. Fay Plasminogen Activator Inhibitor Type 1 Enhances Neointima Formation After Oxidative Vascular Injury in Atherosclerosis-Prone Mice Circulation, June 26, 2001; 103(25): 3105 - 3110. [Abstract] [Full Text] [PDF]

				E. D. Rosen, S. Raymond, A. Zollman, F. Noria, M. Sandoval-Cooper, A. Shulman, J. L. Merz, and F. J. Castellino Laser-Induced Noninvasive Vascular Injury Models in Mice Generate Platelet- and Coagulation-Dependent Thrombi Am. J. Pathol., May 1, 2001; 158(5): 1613 - 1622. [Abstract] [Full Text] [PDF]

				J. Orbe, J. A Rodriguez, A. Calvo, A. Grau, M. S Belzunce, D. Martinez-Caro, and J. A Paramo Vitamins C and E attenuate plasminogen activator inhibitor-1 (PAI-1) expression in a hypercholesterolemic porcine model of angioplasty Cardiovasc Res, February 1, 2001; 49(2): 484 - 492. [Abstract] [Full Text] [PDF]

				S. Konstantinides, K. Schafer, T. Thinnes, and D. J. Loskutoff Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice Circulation, January 30, 2001; 103(4): 576 - 583. [Abstract] [Full Text] [PDF]

				T. Kawasaki, M. Dewerchin, H. R. Lijnen, J. Vermylen, and M. F. Hoylaerts Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice Blood, July 1, 2000; 96(1): 153 - 160. [Abstract] [Full Text] [PDF]

				D. T. Eitzman, R. J. Westrick, E. G. Nabel, and D. Ginsburg Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice Blood, January 15, 2000; 95(2): 577 - 580. [Abstract] [Full Text] [PDF]

				Z. G. Zhang, M. Chopp, A. Goussev, D. Lu, D. Morris, W. Tsang, C. Powers, and K.-L. Ho Cerebral Microvascular Obstruction by Fibrin is Associated with Upregulation of PAI-1 Acutely after Onset of Focal Embolic Ischemia in Rats J. Neurosci., December 15, 1999; 19(24): 10898 - 10907. [Abstract] [Full Text] [PDF]

				S. Madoiwa, N. Komatsu, J. Mimuro, K. Kimura, M. Matsuda, and Y. Sakata Developmental Expression of Plasminogen Activator Inhibitor-1 Associated With Thrombopoietin-Dependent Megakaryocytic Differentiation Blood, July 15, 1999; 94(2): 475 - 482. [Abstract] [Full Text] [PDF]

				Y. Zhu, P. Carmeliet, and W. P. Fay Plasminogen Activator Inhibitor-1 Is a Major Determinant of Arterial Thrombolysis Resistance Circulation, June 15, 1999; 99(23): 3050 - 3055. [Abstract] [Full Text] [PDF]

				W. P. Fay, A. C. Parker, M. N. Ansari, X. Zheng, and D. Ginsburg Vitronectin Inhibits the Thrombotic Response to Arterial Injury in Mice Blood, March 15, 1999; 93(6): 1825 - 1830. [Abstract] [Full Text] [PDF]

				D. Li, S. Weng, B. Yang, D. S. Zander, T. Saldeen, W. W. Nichols, S. Khan, and J. L. Mehta Inhibition of Arterial Thrombus Formation by ApoA1 Milano Arterioscler. Thromb. Vasc. Biol., February 1, 1999; 19(2): 378 - 383. [Abstract] [Full Text] [PDF]

				H. Ishii, M. Yoshida, M. Hiraoka, K. A. Hajjar, A. Tanaka, Y. Yasukochi, and F. Numano Recombinant Annexin II Modulates Impaired Fibrinolytic Activity In Vitro and in Rat Carotid Artery Circ. Res., December 7, 2001; 89(12): 1240 - 1245. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farrehi, P. M. Articles by Fay, W. P. Search for Related Content PubMed PubMed Citation Articles by Farrehi, P. M. Articles by Fay, W. P.